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Abstract
Background: Heptaplatin is a new platinum derivative with anticancer activity against various
cancer cell lines, including cisplatin-resistant cancer cell lines (Cancer Chemother Pharmacol 1995;
35: 441).
Methods: Molecular mechanisms of heptaplatin effective against cisplatin-resistant cancer cell lines
has been investigated in connection with metallothionein (MT). Cytotoxicity was determined by an
MTT assay. MT mRNA, was determined by RT-PCR assay. Transfection study was carried out to
examine the function of MT.
Results: Of various gastric cancer cell lines, SNU-638 and SNU-601 showed the highest and
lowest levels of MT mRNA, respectively, showing 80-fold difference. The IC50 values of SNU-638
to cisplatin, carboplatin and heptaplatin were 11.2-fold, 5.1-fold and 2.0-fold greater than those of
SNU-601, respectively. Heptaplatin was more effective against cisplatin-resistant and MT-
transfected gastric cancer sublines than cisplatin or carboplatin was. In addition, heptaplatin
attenuated cadmium, but not zinc, induction of MT.
Conclusion: These results indicate that molecular mechanisms of heptaplatin effective against
cisplatin-resistant gastric cancer sublines is at least in part due to the less involvement of MT in
heptaplatin resistance as well as its attenuation of MT induction.
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Introduction
Gastric cancer is the most frequently diagnosed and the
second leading cause of cancer-related death in Korea. For
many years, a few single agents such as 5-fluorouracil,
doxorubicin, mitomycin C, and nitrosourea, have been
considered to have significant antitumor activity in gastric
cancer patients [1]. However, the response rate has been
<30% and complete remission has been rare. Several com-
bination chemotherapy regimens such as FAM (5-fluorou-
racil, adriamycin, and mitomycin C) have been attempted
in order to improve the treatment outcomes. In a nonran-
domized Phase II study for advanced gastric cancer, the
FAM regimen achieved an objective partial response rate
of 42% [2]. Some cisplatin-based combination chemo-
therapy regimens have shown high response rates [3,4].
Despite the efficacy of cisplatin against gastric cancer,
there were two major problems with this agent. Firstly,
there are significant side effects, such as severe nausea and
vomiting, nephrotoxicity, and neurotoxicity [5]. Sec-
ondly, the cancer cells show a primary or acquired resist-
ance to cisplatin [6]. Therefore, extensive effort to develop
novel cisplatin analogs with equivalent or greater antitu-
mor activity and a lower toxicity has been made. Among
them, carboplatin has reduced renal and gastrointestinal
side effects than cisplatin [7]. However, carboplatin has
no enhanced therapeutic efficacy over cisplatin and has
not circumvented the acquired resistance to cisplatin.
Therefore, it is essential to develop a new platinum drug
with a greater potent antitumor activity as well as being
effective against resistant cells. Recently, SK Pharmaceuti-
cal (Seoul, Korea) developed many cisplatin analogs,
including heptaplatin (SKI-2053R) (Fig. 1). Heptaplatin
exhibited a greater antitumor activity against a number of
human cancer cell lines including gastric cancer as well as
a lower nephrotoxicity [8,9]. In addition, heptaplatin
2053R is also effective against cisplatin-resistant L1210
leukemia cells (L1210-CPR) [10].
Metallothioneins (MT) are a family of stress-induced pro-
teins with a wide variety of physiological functions,
including protection against metal toxicity and oxidants.
They may also assist in regulating cellular proliferation,
apoptosis, and malignant progression. MT has a high
affinity for heavy metals since it contains many cystein
residues, which account for approximately 30% of the
total amino acids in this protein molecule [11]. MT is a
low molecular weight metal binding protein whose syn-
thesis is induced by heavy metals, glucocorticoids and
other factors [12]. Although the physiological role of MT
is unclear, MT participates in detoxifying heavy metals or
maintaining zinc and copper homeostasis [12]. Some
reports have shown that MT has free radical scavenging
ability in vitro [13,14] and MT expression also increases
the cellular resistance to radiation damage [15]. The cells
transfected with the bovine papilloma virus expression
vectors containing the DNA encoding human metal-
lothionein-IIA were resistant to cisplatin, melphalan, and
chlorambucil but not to 5-fluorouracil or vincristine [16].
In this study, the effect of MT on the cisplatin analog-
induced cytotoxicity was investigated in the gastric cancer
cell lines. Since heptaplatin is less associated with MT, it is
believed to be effective against cisplatin-resistant cells
related to the high level of MT.
Results
MT cDNA, whose expression level was higher than the
wild-type AML-2, were isolated from the paraquat-resist-
ant AML-2 cells [17,18]. The nucleotide sequence of the
clone, containing an almost full-length cDNA copy of the
human MT mRNA, was determined. Molecular cloning
and nucleotide sequence analysis revealed that the hMT
transcript is a novel hMT-I isoform, which was designated
hMT-Ip, and exhibits a 98.4% homology with the hMT-Ie
isoform, whereas it shows 86.9% homology with hMT-II,
83.8% homology with hMT-III and 62.9% homology
with hMT-IV [18].
Structure of cisplatin analogs Figure 1
Structure of cisplatin analogs.
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MT mRNA expression in the gastric cancer cell lines
Using the RT-PCR assay, the MT mRNA was determined in
the 8 human gastric cancer cell lines, SNU-1, SNU-5, SNU-
16, SNU-484, SNU-601, SNU-620, SNU-638, and SNU-
668. The gastric cancer cell lines showed differential
expression level of MT mRNA, in which the SNU-601 cells
expressed the lowest MT mRNA level whereas SNU-638
expressed the highest level (Fig. 2). The MT mRNA level of
SNU-638 was 80 times higher than that of SNU-601.
Comparative sensitivity of the gastric cancer cells that 
express MT differentially to cisplatin analogs
The resistance of the gastric cancer cells that express MT to
cisplatin was compared. SNU-16 and SNU-601, which
showed the lowest MT expression levels, were sensitive
but SNU-638, which exhibited the highest MT expression
levels, were resistant to cisplatin (Fig. 3). On the other
hand, the gastric cancer cell lines expressing moderate MT
expression levels (SNU-16, SNU-484, SNU-620, SNU-5
and SNU-668) showed a lower correlation between the
(A) MT mRNA expression in the gastric cancer cell lines Figure 2
(A) MT mRNA expression in the gastric cancer cell lines. The expression level was determined by RT-PCR assay. β-actin was 
used as a control for RNA. The cDNA reverse-transcribed from the mRNA was individually amplified with each primer pair 
for the MT and β-actin genes. Aliquots of each PCR reaction mixture were separated on 7% polyacrylamide gel in TAE. The gel 
was dried and exposed on X-ray film overnight. (B) The ratio of MT/β-actin of SNU cell lines.
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sensitivity to cisplatin and MT expression (Fig. 3). In addi-
tion, 3 gastric cancer cell lines with very low (SNU-484) or
moderate MT levels (SNU-1 and SNU-620) which are as
resistant to cisplatin as SNU-638 (Fig. 2 and 3), suggesting
no involvement at all of MT in cisplatin resistance or the
involvement of other resistance mechanisms except MT.
Correlation of MT mRNA expression and sensitivity to the 
cisplatin analogs
The cytotoxicity of the cisplatin analogs in the SNU-638
and SNU-601 cells, which expressed different MT levels,
was determined by an MTT assay. The SNU-638 cells were
approximately 11 times, 4 times and 2 times more resist-
ant to cisplatin, carboplatin and heptaplatin, respectively,
than the SNU-601 cells (Fig. 4 and Table 1), suggesting a
lower involvement of MT in the resistance to heptaplatin.
Comparison of resistance to cisplatin analogs in gastric 
cancer sublines resistant to cisplatin
The cisplatin-resistant gastric cancer subline, SNU-601/
Cis was selected in the presence of 2 µg/ml cisplatin. The
SNU-601/Cis cells showed an approximately 49-fold, 56-
fold and 29-fold increased resistance to cisplatin, carbopl-
atin and heptaplatin, respectively (Fig. 5 and Table 1).
Sensitivity of MT-transfected SNU-601 cells to cisplatin 
analogs
Sensitivity to cisplatin analogs was compared between
SNU-601 transfected with the vector containing the full-
length MT cDNA (pIRESneo2/MT) and with the empty
vector (pIRESneo2/Mock).
Although the SNU-601/MT showed a 66% increase in MT
expression when compared to the SNU-601/Mock cells,
the SNU-601/MT cells scavenged significantly ROS gener-
ated by hydrogen peroxide or paraquat as compared with
those in SNU-601/Mock using a fluorescence probe (Fig.
6). This result suggests that SNU-601/MT expresses not
only a higher quantity of MT than does SNU-601/Mock
but also the MT functions to scavenge ROS.
The sensitivities of the SNU-601/MT cells to cisplatin ana-
logs were tested using the MTT assay. The SNU-601/MT
cells showed a lower degree of resistance to cisplatin and
carboplatin, but was paradoxically sensitive to heptapla-
tin when compared to the SNU-601/Mock cells (Fig. 7).
Comparison of MT mRNA expression in SNU-601 after 
treatment of zinc and cisplatin analogs
To examine the effect of zinc and cisplatin analogs on MT
mRNA expression, the maximum non-cytotoxic concen-
trations of each drug in the 3-day MTT assay were chosen
Cytotoxic effect of cisplatin in the gastric cancer cell lines Figure 3
Cytotoxic effect of cisplatin in the gastric cancer cell lines. Cisplatin cytotoxicity was determined using an MTT assay.
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Cytotoxic profiles of the cisplatin analogs in the SNU-601 and SNU-638 cell lines showing low and high MT expression levels,  respectively Figure 4
Cytotoxic profiles of the cisplatin analogs in the SNU-601 and SNU-638 cell lines showing low and high MT expression levels, 
respectively.
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and then treated for 1 day. After the treatment with 100
µM ZnCl2, 0.6 µg/ml cisplatin, 2 µg/ml carboplatin and
0.2  µg/ml heptaplatin for 24 hr, MT mRNA level was
determined using the RT-PCR assay. The MT mRNA
expression level was significantly increased by ZnCl2 but
was decreased by heptaplatin. In contrast, there were no
changes in MT mRNA expression level by cisplatin and
carboplatin (Fig. 8).
Effect of heptaplatin on heavy metal-induced MT 
expression in SNU-601 cells
Of the cisplatin analogs, heptaplatin is not only relatively
less related to MT but also decreases the MT expression
level. We tested whether or not heptaplatin could influ-
ence the heavy metal-induced MT expression. Each IC50
concentration of CdCl2 or ZnCl2 obtained from the 3-day
MTT that did not influence the growth of the SNU-601
cells for 24 hr were used in this study. The SNU-601 cells
were treated with 32 µM CdCl2 or 200 µM ZnCl2 in the
presence or absence of 200 ng/ml heptaplatin for 24 hr.
After a 24-h treatment, MT expression level was deter-
mined by the RT-PCR assay and Western blot analysis. Fig.
9 shows that heptaplatin inhibits the MT gene expression
induced by cadmium but not zinc, suggesting the differen-
tial modulation of metal-induced MT expression.
Discussion
The cisplatin analogs are among the most active and
widely used cytotoxic anticancer drugs. However, the
acquisition or presence of resistance significantly under-
mined the curative potential of these drugs against many
malignancies. Alterations in the cellular pharmacology,
including decreased drug accumulation, increased cellular
thiol levels and increased repair of platinum-DNA dam-
age, have been observed in the cisplatin-resistant cancer
cell lines [19]. Since heptaplatin is effective against cispla-
tin-resistant cancer cells, its development has shed light
on cisplatin-refractory cancer patients. However the
mechanism by which heptaplatin is effective against cispl-
atin-resistant cancer cells is unclear. Since MT is involved
in cisplatin resistance [26], the molecular mechanisms for
the effect of heptaplatin against the cisplatin-resistant can-
cer cell lines was investigated with respect to the involve-
ment of MT. In this study, the gastric cancer cell lines
expressed different basal MT mRNA levels, whose mecha-
nisms remain to be determined. It was suggested that
DNA hypomethylation was responsible for the higher
basal hMT-IIa mRNA levels in the cisplatin-resistant cells
[20]. In this study, MT expression in the gastric cancer cell
lines was not always related to the resistance to cisplatin,
suggesting the involvement of other mechanisms except
MT. But heptaplatin is more effective against the MT-over-
expressing gastric cancer cell line selected for resistance to
cisplatin than cisplatin and carboplatin were. In addition,
the cytotoxicity by cisplatin and carboplatin but not hep-
taplatin was reduced by a pretreatment with zinc, which
can induce MT remarkably (data not shown). Taken
together, heptaplatin was more effective against both cis-
platin-resistant gastric cancer cell subline SNU-601/CIS
and MT-overexpressing SNU-638 than was cisplatin or
carboplatin. These results suggest a possibility that the
cytotoxicity of heptaplatin was less influenced by MT. To
test the hypothesis, the function of MT involved in the
cytotoxicity of the cisplatin analogs was confirmed by the
transfection of MT. The cytotoxicity of heptaplatin was
not influenced by the MT transfection, which indicates
that the anticancer activity of heptaplatin to the cisplatin-
resistant gastric cancer sublines could be less associated
with MT. In addition, heptaplatin inhibited the MT
expression caused by cadmiun but not zinc. This result
suggests that metals differentially regulate MT, which is
supported by the literature. The inhibition mechanism for
H7, a protein kinase C inhibitor, may be different
between the zinc- and cadmium-treated cells. H7 blocks
zinc transport but not cadmium transport although rott-
lerin, a PKC inhibitor that can block both cadmium and
zinc transport [21,22]. Hypoxia activates MT expression
through the metal response elements and that this activa-
tion involves the metal transcription factor-1 (MTF-1)
[23]. MTF-1 was found to be present in the cytoplasm of
the cells. Upon zinc stimulation, MTF-1 was translocated
to the nuclei and activated MT gene expression [24]. How-
ever, no MTF-1 translocation was observed in cells treated
with cadmium [25]. Whether or not MTF-1 is involved in
inhibiting the cadmium-induced MT induction by hepta-
platin remains to be determined.
Table 1: Comparison of cytotoxicities of the cisplatin analogs in 
various gastric cancer cell lines
Ratio of IC50 
a
Cell line Cisplatin Carboplatin Heptaplatin
638/601b 11.23 5.10 2.00*
CIS/601c 50.30 55.95 28.36*
MT/Mockd 54.77e 3.00 1.57*
a, The 50% inhibitory concentration (IC50) for a particular agent was 
defined as the drug concentration which results in a 50% reduction in 
cell number to the untreated control. IC50 values were determined 
directly from semilogarithmic dose-response curves. The means were 
obtained from the experiments carried out at least in triplicate.
b, The ratios of IC50values of SNU-638 to that of SNU-601 (Fig. 4)
c, The ratios of IC50 values of SNU-601/Cis to that of SNU-601 (Fig. 5)
d, The ratios of IC50 values of SNU-601/MT to that of SNU-601/Mock 
(Fig. 7)
e, The ratio calculated from extrapolated data obtained in SNU-601/
MT (Fig. 7) *, P < 0.05 versus cisplatin or carboplatin groupCancer Cell International 2004, 4:6 http://www.cancerci.com/content/4/1/6
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Cytotoxic effects of cisplatin, carboplatin and heptaplatin in the SNU-601/WT cells and its cisplatin-resistant subline SNU-601/ CIS Figure 5
Cytotoxic effects of cisplatin, carboplatin and heptaplatin in the SNU-601/WT cells and its cisplatin-resistant subline SNU-601/
CIS. The cytotoxicity was determined using the MTT assay. Mean ± SE of triplicate determination is given.
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In summary, these results indicate that molecular mecha-
nisms responsible for the effect of heptaplatin against the
cisplatin-resistant gastric cancer sublines is at least in part
due to the lower involvement of MT as well as its attenua-
tion of MT induction.
Materials and Methods
Cell culture and the selection of the gastric cancer cell 
subline for cisplatin resistance
The human gastric cancer cell lines (SNU-1, SNU-5, SNU-
16, SNU-484, SNU-601, SNU-620, SNU-638, and SNU-
668) were obtained from the Cancer Research Center in
Seoul National University (South Korea). The cells were
cultured in RPMI 1640 (GibcoBRL Grand Island, NY,
U.S.A.) supplemented with 10% FBS (Sigma Chemical
Co. St. Louis, MO, U.S.A.). The cells were maintained as a
monolayer culture and subcultured at confluence. The cis-
platin-resistant gastric cancer cell subline was selected by
chronic exposure to gradually increasing cisplatin
concentrations ranging from 200 ng/ml (IC50 value) to
2,000 ng/ml on an intermittent dosage schedule.
Cytotoxicity assay
The in vitro cytotoxicity of the drugs was determined using
an MTT (Sigma Chemical Co. St. Louis, MO, USA) assay
previously described by Pieters et al. [26]. The 50% inhib-
itory concentration (IC50) for a particular agent was
defined as the drug concentration that causes in a 50%
reduction in the number of cells compared to the
untreated control for 3 days. The IC50 values were deter-
mined directly from the semilogarithmic dose-response
curves. Cisplatin and carboplatin were obtained from
Sigma Chemical Co. (St. Louis, MO, USA) and heptapla-
tin (Sunpla®) was generously donated by SK Pharmaceuti-
cal (Seoul, Korea). Cisplatin analogs were dissolved in
phosphate buffered saline and used immediately because
of their instability in aqueous solution.
RNA extraction RT-PCR assay
The total RNA was extracted from the cells using the acid
guanidium thiocyanate-phenol-chloroform method [27].
The MT and β-actin mRNA transcripts were detected using
an RT-PCR assay. The RNA from each sample was reverse
transcribed using 200 units of Moloney murine leukemia
virus reverse transcriptase (GibcoBRL, Grand Island, NY,
U.S.A) and oligo (dT) primer for 1 h at 37°C. The result-
ing cDNA was diluted 1:5 with distilled water and ampli-
fied with 2.5 units of Taq polymerase (Perkin-Elmer,
Foster City, CA, USA) and 10 pmole of each primer using
a GeneAmp PCR2400 (Perkin-Elmer, Foster City, CA,
USA). The MT expression level was detected with the sense
and antisense primers corresponding to the nucleotides
Comparison of ROS-scavenging activities between the SNU-601/Mock and the SNU-601/MT sublines Figure 6
Comparison of ROS-scavenging activities between the SNU-601/Mock and the SNU-601/MT sublines. The reaction took place 
with 1 × 105 cells and 1 µM 2',7'-DCFH diacetate in 3 ml phosphate-buffered saline. The cells were exposed to H2O2 and 
paraquat for 4 hours. The fluorescence intensity was determined using a fluorometer with excitation wavelength at 485 and 
emission wavelength at 530 nm. The results are expressed as means ± SE (n = 3). PQ, paraquat; *, P < 0.05.Cancer Cell International 2004, 4:6 http://www.cancerci.com/content/4/1/6
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Cytotoxic effects of cisplatin, carboplatin and heptaplatin in the SNU-601/Mock and SNU-601/MT sublines Figure 7
Cytotoxic effects of cisplatin, carboplatin and heptaplatin in the SNU-601/Mock and SNU-601/MT sublines. Cytotoxicity was 
determined using the MTT assay. Mean ± SE of triplicate determination is given.Cancer Cell International 2004, 4:6 http://www.cancerci.com/content/4/1/6
Page 10 of 12
(page number not for citation purposes)
(5'-ATGGACCCCAACTGCTCG) and (5'-TCAGGCGCAG-
CAGCTGCA), respectively, of the published cDNA
sequence [28] and yielded a 220-bp PCR product. The β-
actin expression level, as a control of the RNA quantity,
was detected with the sense and antisense primers corre-
sponding to the nucleotides 1912–1932 (5'-GACTAT-
GACTTAGTTGCGTTA) and 2412–2392 (5'-
GCCTTCATACATCTCAAGTTG), respectively, of the
published cDNA sequence [29], yielding a 501-bp PCR
product. Twenty one PCR cycles for MT was carried out as
follows: denaturation at 94°C for 30 s, annealing at 57°C
for 60 s, and extension at 72°C for 1 min was used. Six-
teen cycles of PCR for β-actin of denaturation at 95°C for
30 s, annealing at 53°C for 30 s, and extension at 72°C for
30 s. After the last cycle, all the PCR products were sub-
jected to a final extension for 5 min at 72°C. For quanti-
tation, 5 mCi/ml of [α-32P] dCTP was added to each
reaction mixture. Subsequently, the PCR products were
combined and electrophoresed on 7.5% nondenaturing
polyacrylamide gels. The bands were scanned using a den-
sitometer (Pdi, Huntington Station, NY, USA). The
quantity of each mRNA transcript was normalized with
that of β-actin mRNA. Autoradiographic films of the RT-
PCR assay were subjected to densitometric analysis using
a densitometer.
Protein extraction and Western blot analysis for MT
The total cell lysates from 2 × 106 cells were prepared by
lysing the harvested cells in an extraction buffer (1% NP-
40, 0.5% sodium deoxycholate, 0.1% SDS in phosphate-
buffered saline) supplemented with 2 mM phenylmethyl-
sulfonyl fluoride (Sigma Chemical Co. St. Louis, MO,
USA) and 10 µg/ml leupeptin (Sigma Chemical Co. St.
Louis, MO, USA). The DNA was sheared by sonication.
The sample buffer for MT analysis was used without 2-
mercaptoethanol [30]. Western blotting analysis was
performed using a slight modification of the method
reported by Towbin et al. [31]. The proteins were trans-
ferred onto a nitrocellulose membrane by electroblotting
at a current of 60 V overnight using a transfer buffer con-
taining 5% mercaptoethanol. The membrane was incu-
bated in a blocking solution (5% skim milk) for 1 hr at
room temperature, washed, and then incubated with a
monoclonal mouse antibody (E9 clone, 1:500, Dako Cor-
poration, Carpinteria. CA, USA) for MT-I and MT-II. The
membrane was washed and incubated with horseradish
peroxidase-conjugated secondary antibodies (diluted
1:1000) for 1 hr. The membrane was then stained using
the ECL detection kit (Amersham Biosciences Corp., Pis-
cataway, NJ, USA).
Production of stable transfectant cell line
Mammalian transfectants were produced as reported pre-
viously [18]. The mammalian expression vector,
pIRESneo2 (Clonetech, Palo Alto, CA, USA), was used to
clone the MT. A 220 base pair cDNA fragment containing
the full open reading frame of human MT was amplified
by RT-PCR from the RNA of AML-2/PQ400 [17], a
paraquat-resistant AML-2 cell line that highly over-
expresses MT. The PCR primer pairs were as follows: the
forward primer 5'-CGGGATCCATGGACCCCAACT-
GCTCG-3' to introduce a BamH I site as underlined, and
reverse primer: 5'ATAAGAATGCGGCCGCTCAGGCG-
CAGCAGCTGCA-3' to introduce a Not  I site as
underlined. The resulting MT PCR product was cloned to
a TOPO TA cloning kit (Invitrogen, Carlsbad, CA, USA).
After confirmation of the sequencing, the MT was cut
from the TOPO plasmid vector (pCR 2.1-TOPO), puri-
fied, subcloning to the multicloning site of the expression
vector pIRESneo2 and subsequently sequenced to confirm
the correct open reading frame. Transfection was per-
formed using the LipofectAmine Plus reagents (GIBCO
BRL, Grand Island, NY, USA). Approximately 1 × 106 of
the SNU-601 cells were plated into a 60 mm tissue culture
MT expression in the SNU-601 cell line after a treatment with zinc and the cisplatin analogs Figure 8
MT expression in the SNU-601 cell line after a treatment with zinc and the cisplatin analogs. The SNU-601 cells were treated 
with 100 µM ZnCl2, 0.6 µg/ml cisplatin, 2 µg/ml carboplatin, 0.2 µg/ml heptaplatin for 24 hrs. The MT mRNA expression level 
was determined by the RT-PCR assay.
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dish and cultured overnight. Prior to transfection, the
growth medium was replaced with the serum free RPMI
1640 media and cultured. The LipofectAmine reagent
containing 2 µg of pIRES/Mock and pIRES/MT was com-
bined with the Plus reagent and applied to the cells. After
culturing for five hours, the media was replaced with
RPMI 1640 containing 10% FBS. After selection by culture
in the medium containing 0.2 mg/ml of G-418 (GIBCO
BRL, Grand Island, NY, USA), the emerging colonies were
isolated with cloning rings. The stable transfectants, SNU-
601/Mock and SNU-601/MT, were obtained. The selec-
tion medium was changed every 2–3 days.
Determination of reactive oxygen species (ROS) using a 
fluorometric probe
Dichlorofluorescin (DCFH) was used to measure the ROS
concentration. After 2', 7'-dichlorofluorescin diacetate
(DCFH-DA) crosses the membrane, it is de-esterified to
Effect of heptaplatin on MT induction by heavy metals in the SNU-601 cell lines Figure 9
Effect of heptaplatin on MT induction by heavy metals in the SNU-601 cell lines. The SNU-601 cells were treated with 32 µM 
CdCl2 or 200 µM ZnCl2 in the presence or absence of 200 ng/ml heptaplatin for 24 hr. The MT expression level was deter-
mined by (A) the RT-PCR assay and (B) the Western blotting method.
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DCFH which is oxidized to fluorescent DCF by the ROS
[32]. Phosphate-buffered saline containing 1 × 105/ml
SNU-601/Mock or the SNU-601/MT cells was incubated
with 1 µM DCFH-DA at 37°C for 4 hr. After incubation,
the DCF fluorescence intensity was determined using a
fluorometer at 485 nm for excitation and 530 nm for
emission.
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